Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CLOVIS ONCOLOGY INC (CLVS) Stock Price & Overview
NASDAQ:CLVS • US1894641000
Current stock price
0.0812 USD
0 (-5.58%)
At close:
0.078 USD
0 (-3.94%)
After Hours:
The current stock price of CLVS is 0.0812 USD. Today CLVS is down by -5.58%. In the past month the price decreased by -76.84%. In the past year, price decreased by -97.44%.
CLVS Key Statistics
52-Week Range0.076 - 3.25
Current CLVS stock price positioned within its 52-week range.
1-Month Range0.076 - 0.3772
Current CLVS stock price positioned within its 1-month range.
- Market Cap
- 11.77M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.81
- Dividend Yield
- N/A
CLVS Stock Performance
Today
-5.58%
1 Week
-39.04%
1 Month
-76.84%
3 Months
-92.75%
Longer-term
6 Months -95.22%
1 Year -97.44%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
CLVS Stock Chart
CLVS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CLVS. When comparing the yearly performance of all stocks, CLVS is a bad performer in the overall market: 99.49% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CLVS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLVS. CLVS has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CLVS Earnings
Next Earnings DateFeb 21, 2023
Last Earnings DateNov 9, 2022
PeriodQ3 / 2022
EPS Reported-$0.39
Revenue Reported
EPS Surprise 7.49%
Revenue Surprise -9.51%
CLVS Forecast & Estimates
7 analysts have analysed CLVS and the average price target is 2.04 USD. This implies a price increase of 2412.32% is expected in the next year compared to the current price of 0.0812.
For the next year, analysts expect an EPS growth of 28.29% and a revenue growth -14% for CLVS
Analysts
Analysts42.86
Price Target2.04 (2412.32%)
EPS Next Y28.29%
Revenue Next Year-14%
CLVS Financial Highlights
Over the last trailing twelve months CLVS reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 36.04% compared to the year before.
Income Statements
Revenue(TTM)133.02M
Net Income(TTM)-251.91M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%30.36%
Sales Q2Q%-19.13%
EPS 1Y (TTM)36.04%
Revenue 1Y (TTM)-14.78%
CLVS Ownership
Ownership
Inst Owners0%
Shares144.96M
Float142.20M
Ins Owners5.92%
Short Float %N/A
Short RatioN/A
CLVS Industry Overview
CLVS operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
CLVS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLVS
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
Company Info
IPO: 2011-11-16
CLOVIS ONCOLOGY INC
Suite 100, 2525 28Th Street
Boulder COLORADO 80301 US
CEO: Patrick J. Mahaffy
Employees: 413
Phone: 13036255000.0
CLOVIS ONCOLOGY INC / CLVS FAQ
Can you describe the business of CLOVIS ONCOLOGY INC?
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
What is the stock price of CLOVIS ONCOLOGY INC today?
The current stock price of CLVS is 0.0812 USD. The price decreased by -5.58% in the last trading session.
What is the dividend status of CLOVIS ONCOLOGY INC?
CLVS does not pay a dividend.
How is the ChartMill rating for CLOVIS ONCOLOGY INC?
CLVS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does CLOVIS ONCOLOGY INC belong to?
CLOVIS ONCOLOGY INC (CLVS) operates in the Health Care sector and the Biotechnology industry.
Who owns CLOVIS ONCOLOGY INC?
You can find the ownership structure of CLOVIS ONCOLOGY INC (CLVS) on the Ownership tab.